1Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut, 1994, 35: 360-362.
2Campieri M. New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut, 2002, 50 Suppl 3: 11143-11146.
3Camma C, Giunta M, Rpsselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a metaanalysis adjusted for confounding variables, Gastroenterology, 1997, 113:1465-1473.
4Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev, 2002, 15: 79-94.
5Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease:a 30 year review. Gut, 2002, 50: 485-489.
6Loftus CG, Loftus EV Jr, Sandborn WJ. Cyclosporin for refractory ulcerative colitis. Gut, 2003, 52: 172-173.
7Stallmach A, Wittig BM, Moser C, Fischinger J, Duchmann R, Zeitz M. Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. Gut, 2003, 52: 377-382.
8ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut,2002, 50: 206-211.
9Rutgeerts P, D'haens G, Targan S, Vasiliauskas E,Hanauer SB, Present DH, Mayer L, Van Hogezand RA,Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.Gastroenterology, 1999, 117:761 -769.
10D'haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K,Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European muhicenter trial. Gastroenterology,1999, 116: 1029-1034.
同被引文献11
1Munkholm P,Langholz E,Davidsen M,Binder V.Frequency of glucocorticoid resistance and dependency in Crohn's disease.Gut 1994; 35:360-362.
2Papadakis KA,Tung JK,Binder SW,Kam LY,Abreu MT,Targan SR,Vasiliauskas EA.Outcome of cytomegalovirus infections in patients with inflammatory bowel disease.Am J Gastroenterol 2001; 96:2137-2142.
3Truelove SC,Witts LJ.Cortisone in ulcerative colitis; final report on a therapeutic trial.Br Med J 1955; 2:1041-1048.
4Stange EF,Travis SP,Vermeire S,Beglinger C,Kupcinkas L,Geboes K,Barakauskiene A,Villanacci V,Von Herbay A,Warren BF,Gasche C,Tilg H,Schreiber SW,Scholmerich J,Reinisch W.European evidence based consensus on the diagnosis and management of Crohn's disease:definitions and diagnosis.Gut 2006; 55 Suppl 1:i1-i15.
5Goodgame RW.Gastrointestinal cytomegalovirus disease.Ann Intern Med 1993; 119:924-935.
6de la Hoz RE,Stephens G,Sherlock C.Diagnosis and treatment approaches of CMV infections in adult patients.J Clin Virol 2002; 25 Suppl 2:S1-S12.
7Vega R,Bertrán X,Menacho M,Domènech E,Moreno de Vega V,Hombrados M,Cabré E,Ojanguren I,Gassull MA.Cytomegalovirus infection in patients with inflammatory bowel disease.Am J Gastroenterol 1999; 94:1053-1056.
8Rahbar A,Bostrom L,Lagerstedt U,Magnusson I,Soderberg-Naucler C,Sundqvist VA.Evidence of active cytomegalovirus infection and increased production of IL-6 in tissue specimens obtained from patients with inflammatory bowel diseases.Inflamm Bowel Dis 2003; 9:154-161.
9Mendez JC,Espy MJ,Smith TF,Wilson JA,Paya CV.Evaluation of PCR primers for early diagnosis of cytomegalovirus infection following liver transplantation.J Clin Microbiol 1998; 36:526-530.
